Global Intravenous Iron Drugs Market 2017-2021

Overview of the global intravenous iron drugs market

According to Technavio’s market research analysts, the global intravenous iron drugs market will grow at a steady rate and post a CAGR of more than 10% during the forecast period. The growing demand for non-dextran IV iron drugs will drive the growth prospects for the global intravenous iron drugs market until the end of 2021. The market is witnessing a high degree of shift from conventional dextran intravenous iron drugs to non-dextran intravenous iron drugs due to the growing demand for non-dextran intravenous iron drugs, which in turn, will fuel the market’s growth in the coming years. One of the major factors responsible for the growing demand for non-dextran intravenous iron drugs is its ability to deliver larger doses of iron infusion in a short time. Furthermore, these drugs also have the ability to address challenges such as intolerance or an unsatisfactory response, safety concerns, and dosing and compliance issues associated with conventional iron therapies, which will again, fuel their demand in the coming years.

The increase in favorable guidelines from health care organizations will drive the growth prospects for the global intravenous iron drugs market for the next four years. For instance, the European Society of Cardiology posted guidelines that strongly recommend the use of Ferinject for the treatment of iron deficiency in patients with systolic heart failure, in turn, driving the adoption rate of intravenous iron drugs.

Competitive landscape and key vendors